This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19. It will also learn about the safety of drug Ratutrelvir. Participants will take a study drug as well as a standard therapy. A descriptive statistics will be used to present the study results.
Confirmed SARS-CoV-2 infection for 120 h prior to randomization.
Initial onset of signs/symptoms attributable to COVID-19 within 5 days prior to randomization.
History, current need for hospitalization or anticipated need for hospitalization for the medical treatment of COVID-19.
Urgent or expected need for nasal high-flow oxygen therapy or positive pressure ventilation, invasive mechanical ventilation or ECMO.
Known medical history of active liver disease .
Receiving dialysis or history of moderate to severe renal impairment.
Traws Pharma, Inc.
Lead sponsor